ArticleEuropean journal of medical research2025
Analysis of pathogen spectrum in bronchoalveolar lavage fluid, T lymphocyte depletion, and prognosis in patients with severe pneumonia complicated by ARDS.
Article in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
objectiveTo investigate differences in alveolar lavage fluid pathogen spectrum, T lymphocyte subsets, and prognosis between patients with severe pneumonia with and without acute respiratory distress syndrome (ARDS).
methodsA retrospective cohort study was conducted, enrolling 160 patients with severe pneumonia admitted to our hospital between April 1, 2021, and April 1, 2025. Among them, 80 patients had ARDS (ARDS group) and 80 did not (Non-ARDS group). Bronchoalveolar lavage fluid (BALF) was collected for t-NGS pathogen detection, T lymphocyte subset analysis, and 28-day prognosis assessment.
results1. Pathogens Profile: The ARDS group exhibited significantly higher BALF prevalence of Escherichia coli (15.0% vs 2.5%, P = 0.005), Enterococcus faecium (22.5% vs 5.0%, P = 0.001), and Candida albicans (25.0% vs 10.0%, P = 0.013) were significantly higher than in the Non-ARDS group. 2. Immunological Characteristics: In the entire cohort, the ARDS group exhibited significantly lower counts of total T lymphocytes, CD4+, and CD8+ T cells. After excluding patients with viral infections, only the CD8+ T cell count remained significantly different (P = 0.041). 3. PROGNOSIS: The 28-day mortality rate was significantly higher in the ARDS group than in the Non-ARDS group (Log-rank P < 0.001), with a 3.77-fold increased risk of death (HR = 3.77, 95% CI: 1.98-7.15). 4. RISK FACTORS: Multivariable Cox regression analysis across the entire cohort identified vasoactive drug use, Escherichia coli and Candida albicans infections, and elevated CD4+/CD8+ ratios as independent risk factors for mortality. After excluding patients with viral infections, the independent risk factors shifted to vasoactive drugs, Escherichia coli, CRP, and AST. Detailed hazard ratios with confidence intervals are presented in the Results section.
conclusionPatients with severe pneumonia complicated by ARDS exhibit a distinct gut-derived pathogen spectrum and T-cell immune exhaustion, associated with poorer outcomes. Mortality risk in the full cohort was independently associated with vasoactive drug use, specific pathogen infections (E. coli, Candida albicans), and immune dysregulation (elevated CD4+/CD8+ ratio). In the non-viral infection subgroup, core immune deficiency manifested as specific depletion of CD8+ T cells, and mortality drivers shifted to vasoactive drug use, E. coli infection, systemic inflammation (CRP), and liver injury (AST). This study provides evidence for precise risk stratification and personalized treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.